Which imaging modality tells the truth? Correlation between PSMA/MRI/US and pathology
Poster Session 21
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 270

Which prostate cancers are overlooked by mpMRI? An analysis from PROMIS
1University College London, UCL Division of Surgery & Interventional Science, London, United Kingdom, 2Frimley Health NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3University College London, Medical Research Council (MRC) Clinical Trials Unit, London, United Kingdom, 4Taunton & Somerset NHS Foundation Trust, Dept. of Urology, Taunton, United Kingdom, 5University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, 6University College London Hospitals NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, 7Whittington Health NHS Trust, Dept. of Urology, London, United Kingdom, 8Maidstone & Tunbridge Wells NHS Trust, Dept. of Urology, Tunbridge Wells, United Kingdom, 9Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke, United Kingdom, 10University College London Hospitals NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, 11Public & Patient Representative, Public & Patient Representative, Nottingham, United Kingdom, 12The Royal Marsden NHS Foundation Trust, Dept. of Academic Urology, London, United Kingdom, 13North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, 14Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Sheffield, United Kingdom, 15Wrexham Maelor Hospital NHS Trust, Dept. of Urology, Wrexham, United Kingdom, 16Imperial College London, Dept. of Surgery & Cancer, London, United Kingdom

271

Diagnostic performance of biparametric MRI of the prostate (bp-MRI) in biopsy-naive men with suspect of prostate cancer: Intermediate data of a phase II study
By: De Luca S. 1, Fiori C. 1, Russo F. 2, Niculescu R.G. 1, Manfredi M. 1, Amparore D. 1, Checcucci E. 1, Peretti D. 1, Pecoraro A. 1, Aimar R. 1, De Cillis S. 1, Di Dio M. 1,
A lesion specific analysis of the performance of multiparametric MRI in detection of clinically significant prostate cancer in the PART feasibility trial

By: Philippou Y., Campbell A., Leiblich A., Brewster S., Bell R.W., Bryant R.J., Leslie T., Hamdy F.C., Verrill C., Markham H., Morgan S., Macpherson R., Gleeson F., Lamb A.D.

Detection of Intraprostatic Tumor Localisation with 18-Fluorine Prostate-Specific Membrane Antigen (PSMA) PET/CT compared to Radical Prostatectomy Specimens: Is PSMA-targeted biopsy feasible? the DeTeCT trial


How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series


Accuracy and variation of biparametric prostate MRI reporting across a range of reader experience: The global BooMeR Study - initial results

Taneja S. 10, Barrett T. 11, Westphalen A. 12, Schoots I. 13, Grummet J. 1
1Monash University, Dept. of Surgery, Melbourne, Australia, 2Essen University, Dept. of Urology, Essen, Germany, 3University of Cologne, Dept. of Radiology, Cologne, Germany, 4Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, 5University College London, Dept. of Urology, London, United Kingdom, 6Tor Vergata University, Dept. of Urology, Rome, Italy, 7University of Chicago, Dept. of Urology, Chicago, United States of America, 8Deakin University, Dept. of Radiology, Geelong, Australia, 9Stanford University, Dept. of Radiology, Stanford, United States of America, 10New York University Langone, Dept. of Urology, New York City, United States of America, 11Cambridge University, Dept. of Radiology, Cambridge, United Kingdom, 12University of California San Fransisco, Dept. of Radiology, Cambridge, United States of America, 13Erasmus MS University, Dept. of Radiology, Rotterdam, The Netherlands

276

Combined clinical characteristics and multiparametric MRI parameters for prediction of cribriform morphology in intermediate-risk prostate cancer

By: Gao J. 1, Zhang Q. 1, Fu Y. 2, Guo H. 1
1Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, 2Nanjing Drum Tower Hospital, Dept. of Pathology, Nanjing, China

277

Diagnostic accuracy of ADC value on biparametric MRI for detecting clinically significant prostate cancer

Pusan National University Hospital, Dept. of Urology, Busan, South Korea

278

The role of 68Ga-PSMA PET/MRI in the detection and localisation of prostate cancer: The SAMURAI study

By: Cheng J. 1, Pan Y.C. 1, Kalapara A. 2, O’sullivan R. 3, Beech P. 4, Ryan A. 5, Landau A. 6, Bradley J. 7, McIntyre R. 7, Ferris N. 7, Chen Z. 7, Tahayori B. 7, Ramdave S. 7, Frydenberg M. 6, Egan G. 7, Grummet J. 8
1Monash University, Monash School of Medicine, Melbourne, Australia, 2Monash University, Dept. of Surgery, Melbourne, Australia, 3Bridge Road Imaging, Dept. of Radiology, Melbourne, Australia, 4The Alfred Hospital, Dept. of Radiology, Melbourne, Australia, 5TissuPath, Dept. of Pathology, Melbourne, Australia, 6Australian Urology Associates, Dept. of Urology, Melbourne, Australia, 7Monash Biomedical Imaging, Dept. of Biomedical Imaging, Melbourne, Australia, 8The Alfred Hospital, Dept. of Urology, Melbourne, Australia

279

The role of multiparametric MRI and 68-Ga-PSMA PET/MRI in determining the location of index tumor in radical prostatectomy specimen

By: Cosar U. 1, Şen I. 1, Aydos U. 2, Koparal M.Y. 3, Uçar M. 4, Tokgöz N. 4, Gönül İ.I. 5, Akdemir Ü.Ö. 2, Atay L.Ö. 2, Sözen T.S. 1
1Gazi University School of Medicine, Dept. of Urology, Ankara, Turkey, 2Gazi University School of Medicine, Dept. of Nuclear Medicine, Ankara, Turkey, 3Recep Tayyip Erdogan University Training and Research Hospital, Dept. of Urology, Rize, Turkey, 4Gazi
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
</table>
| 280 | Micro-ultrasound imaging of men with family history of prostate cancer: Subpopulation analysis from a multi-institution randomized clinical trial | By: Pavlovich C.  
1Johns Hopkins University Brady Urological Institute, Dept. of Urology, Baltimore, United States of America,  
2University of Calgary, Prostate Centre Calgary, Dept. of Urology, Calgary, Canada,  
3Urology of Virginia, Dept. of Urology, Virginia Beach, United States of America,  
4University Health Network, Joint Dept. of Medical Imaging, Toronto, Canada,  
5CHU de Quebec-Laval University, Dept. of Surgery, Quebec, Canada | University of Medicine, Dept. of Radiology, Ankara, Turkey  
Gazi University School of Medicine, Dept. of Pathology, Ankara, Turkey |
| 281 | Radiomic analysis of T2 and ADC mpMRI images in the diagnosis of clinical significant prostate cancer: An early experience | By: Prata F.  
Campus Biomedico, University of Rome, Dept. of Urology, Rome, Italy,  
Campus Biomedico, University of Rome, Computer Science and Bioinformatics Laboratory, Integrated Research Centre, Rome, Italy | University of Medicine, Dept. of Radiology, Ankara, Turkey  
Gazi University School of Medicine, Dept. of Pathology, Ankara, Turkey |
| 282 | Predictive power of non-invasive mp-MRI markers for clinically significant prostate cancer | By: Goncharuk D.  
Russian Medical Academy of Continuous Professional Education, Dept. of Urology and Surgical Andrology, Moscow, Russia,  
Patero Clinic, Dept. of Radiology, Moscow, Russia,  
Botkin Memorial Hospital, Dept. of Pathomorphology, Moscow, Russia,  
Botkin Clinical Hospital, Dept. of Pathomorphology, Moscow, Russia | University of Medicine, Dept. of Radiology, Ankara, Turkey  
Gazi University School of Medicine, Dept. of Pathology, Ankara, Turkey |
| 283 | Correlation between hybrid PSMA PET MRI and histopathology at radical prostatectomy | By: Mehawed G.  
Princess Alexandra Hospital, Dept. of Urology, Brisbane, Australia,  
Princess Alexandra Hospital, Dept. of Radiology, Brisbane, Australia | University of Medicine, Dept. of Radiology, Ankara, Turkey  
Gazi University School of Medicine, Dept. of Pathology, Ankara, Turkey |